Analysis of demographic and clinical characteristics of primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis patients

Analysis of demographic and clinical characteristics of primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis patients

Bibliographic Details
Main Authors:	P. Akyol, A. Yıldız, M. Albayrak, H. Afacan Öztürk, S. Maral, M. Reis Aras, F. YıLmaz, B. Saglam, M. Tıglıoglu, U. Malkan
Format:	Article
Language:	English
Published:	Elsevier 2020-10-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S253113792030167X

Similar Items

The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia
by: Monika Conchon
Published: (2011-12-01)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
by: Z. Xu, et al.
Published: (2022-06-01)

JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia
by: Bárbara da Costa Reis Monte-Mór, et al.
Published: (2007-03-01)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
by: Hisashi Ishida, et al.
Published: (2020-07-01)

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
by: Fulvia Pimpinelli, et al.
Published: (2021-07-01)

PB2211: DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE: A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA
by: Shengjie Wang, et al.
Published: (2023-08-01)

CLINICAL, CYTOGENETIC AND MOLECULAR CHARACTERIZATION OF BRAZILIAN COHORT PATIENTS WITH PRIMERY MYELOFIBROSIS AND MYELOFIBROSIS POST-POLYCYTTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA
by: RS Tavares, et al.
Published: (2021-10-01)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
by: Leona Dold, et al.
Published: (2021-09-01)

P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT
by: B. Mora, et al.
Published: (2022-06-01)

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018
by: Mónica Mejía-Ochoa, et al.
Published: (2019-06-01)

Updates in the management of polycythemia vera and essential thrombocythemia
by: Prithviraj Bose, et al.
Published: (2019-08-01)

Targeted Sequencing of Sorted Peripheral Blood Cells Reveals Novel Germline and Somatic Variants in the Polymorphonuclear and Mononuclear Cells of Patients with Essential Thrombocythemia, Polycythemia Vera and Primary Myelofibrosis
by: Wong, C.L., et al.
Published: (2015)

Acute phase reactants in chronic inflammation leading to secondary myelofibrosis in polycythemia vera and essential thrombocytosis
by: E. Aladag, et al.
Published: (2020-10-01)

Neuropsychiatric disturbance detecting polycythemia vera myelofibrosis: a case report and literature review
by: Li Li, et al.
Published: (2023-09-01)

Hypercalcemia due to the interaction between all trans retinoic acid and posaconazole used for acute promyelocytic leukemia treatment
by: H. Afacan Öztürk, et al.
Published: (2020-10-01)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
by: Alessandra Carobbio, et al.
Published: (2023-07-01)

Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera
by: Sylvain Lescuyer, et al.
Published: (2019-03-01)

DEREGULATION OF BONE MARROW EICOSANOIDS IN ESSENTIAL THROMBOCYTHEMIA AND PRIMARY MYELOFIBROSIS PATIENTS
by: J.G. Cominal, et al.
Published: (2020-11-01)

Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera
by: M A Sokolova, et al.
Published: (2016-12-01)

Recurrent and Multiple Intracerebral Hemorrhages in Polycythemia Vera Secondary to Myelofibrosis: A Case Report and Literature Review
by: Hidenari Hasui, et al.
Published: (2022-06-01)

Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease
by: A L Melikyan, et al.
Published: (2017-07-01)

Red Blood Cell Contribution to Thrombosis in Polycythemia Vera and Essential Thrombocythemia
by: Julien M. P. Grenier, et al.
Published: (2024-01-01)

The prognostic impact of comorbidity, nutritional and performance status on patients with diffuse large B cell lymphoma
by: B. Saglam, et al.
Published: (2020-10-01)

Disease and clinical characteristics of patients with chronic myeloproliferative neoplasms: 11-year single center experience
by: P. Akyol, et al.
Published: (2020-10-01)

Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report
by: Andreas Hanssønn Habberstad, et al.
Published: (2018-04-01)

DNA Methylation Profiling of Sorted Peripheral Blood Cells Using Microarray and Next Generation Sequencing Reveals Distinct Molecular Signatures in the Polymorphonuclear and Mononuclear Cells of Patients with Essential Thrombocythemia, Polycythemia Vera and Primary Myelofibrosis
by: Wong, C.L., et al.
Published: (2015)

<i>TET2</i> rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis
by: Diana L. Lighezan, et al.
Published: (2020-12-01)

Case report: Effectiveness of low-dose methotrexate monotherapy in post-essential thrombocythemia myelofibrosis
by: Sebastian Francis, et al.
Published: (2024-04-01)

Recent advances in understanding myelofibrosis and essential thrombocythemia [version 1; referees: 2 approved]
by: William Vainchenker, et al.
Published: (2016-04-01)

Morphological, clinical, and molecular profiling of post-polycythemia vera accelerated/blast phase occurring with and without antecedent secondary myelofibrosis
by: Laura Pelagatti, et al.
Published: (2024-04-01)

The Impact of Hematological Parameters on Survival for Patients with COVID-19
by: Fatma YILMAZ, et al.
Published: (2022-12-01)

THE IMPACT OF HEMATOLOGICAL PARAMETERS ON SURVIVAL FOR PATIENTS WITH COVID-19
by: Fatma YILMAZ, et al.
Published: (2021-11-01)

Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance
by: Kittitat Chiaranairungrot, et al.
Published: (2022-12-01)

Single Centre Experience: Bening and Malign Hematological Patients with COVID-19
by: Ümit Yavuz Malkan, et al.
Published: (2022-06-01)

The Sarawak Myelofibrosis (SaMy) experience: Demographics and outcome of myelofibrosis patients in Sarawak, Malaysia
by: Andy Sing Ong Tang, et al.
Published: (2023-09-01)

Easily Applicable Predictive Score for Differential Diagnosis of Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia
by: Danijela Lekovic, et al.
Published: (2023-08-01)

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis
by: İpek Yonal, et al.
Published: (2016-05-01)

The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease’s phenotype
by: Patryk Sobieralski, et al.
Published: (2023-08-01)

Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia
by: Monica Sacco, et al.
Published: (2020-03-01)

Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study
by: Vincenzo Accurso, et al.
Published: (2019-12-01)